Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.88 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21985110 | 1.00 | DPP4 (0.88) | DPP4DPP8DPP7CYP3A4DPP9 | |
| SCHEMBL24244598 | 0.88 | DPP4 (0.79) | DPP4DPP8DPP7CYP3A4DPP9 | |
| SCHEMBL28434489 | 0.88 | DPP4 (0.79) | DPP4DPP8DPP7CYP3A4DPP9 | |
| SCHEMBL25840236 | 0.86 | DPP4 (0.77) | DPP4DPP8DPP7CYP3A4DPP9 | |
| SCHEMBL4699518 | 0.85 | DPP4 (0.68) | DPP4DPP7CYP3A4DPP9 | |
| SCHEMBL4699986 | 0.85 | DPP4 (0.68) | DPP4DPP7CYP3A4DPP9 | |
| SCHEMBL21985114 | 0.84 | DPP4 (0.84) | DPP4DPP7CYP3A4DPP9 | |
| SCHEMBL21985108 | 0.84 | DPP4 (0.68) | DPP4DPP7CYP3A4DPP9 | |
| SCHEMBL29142108 | 0.84 | DPP4 (0.68) | DPP4DPP7CYP3A4DPP9 | |
| SCHEMBL21985104 | 0.84 | DPP4 (0.68) | DPP4DPP7CYP3A4DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459549-B2 | Method for biocatalytic synthesis of Sitagliptin and intermediate thereof | CHINA FORTUNE WAY COMPANY (CN) | 2022-10-04 | — | — | US | disclosed |
| US-20210123080-A1 | METHOD FOR BIOCATALYTIC SYNTHESIS OF SITAGLIPTIN AND INTERMEDIATE THEREOF | CHINA FORTUNE WAY COMPANY (CN) | 2021-04-29 | — | — | US | disclosed |
| EP-3650537-A1 | USE OF STEREOSELECTIVE TRANSAMINASE IN ASYMMETRIC SYNTHESIS OF CHIRAL AMINE | Abiochem Biotechnology Co., Ltd. (CN) | 2020-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210123080-A1 | METHOD FOR BIOCATALYTIC SYNTHESIS OF SITAGLIPTIN AND INTERMEDIATE THEREOF | DPP4, SI, DPP9 | DPP4 1/4885DPP8 12/4885DPP7 4/4885 |
| US-11459549-B2 | Method for biocatalytic synthesis of Sitagliptin and intermediate thereof | DPP4, SI, DPP9 | DPP4 1/4885DPP8 12/4885DPP7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.